Literature DB >> 15736157

Potential neuroprotective effect of t-butylhydroquinone against neurotoxicity-induced by 1-methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine (2'-methyl-MPTP) in mice.

M H Abdel-Wahab1.   

Abstract

Dopaminergic damage inducing Parkinson's disease (PD) is ubiquitous neurodegenerative disorder, characterized by the progressive loss of dopaminergic neurons in the nigrostriatal pathways. The etiology and pathogenic factors implicated in dopaminergic damage are still unexplored to develop causal therapeutic strategies aimed to halt its progressive loss. The neurotoxicity induced by 1-methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine (2'CH3-MPTP), which is more potent neurotoxic than MPTP in mice, is one of the most valuable models for analyzing pathological feature of dopaminergic damage. Herein, we investigated the neuroprotective effect of the potent antioxidant tertiary butylhydroquinone (TBHQ) against 2'CH3-MPTP-induced neurotoxicity in mice as well as the possible mechanism underlying such neurotoxicity. Male albino mice were injected with two doses of 2'CH3-MPTP (20 mg/kg, i.p.) for two consecutive days. Animals were killed after 2 weeks from the last dose of 2'CH3-MPTP. Control animals received 10 mL/kg body weight i.p. of distilled water. In both groups, brain stems containing the nigrostriatal pathways were dissected and reduced glutathione (GSH), malonyldialdehyde (MDA) contents, and superoxide dismutase (SOD) activity were estimated. Also, brain stem histopathological and histochemical changes were examined. The results of this study revealed that i.p. injection of 2'CH3-MPTP caused decrease in the brain stem content of GSH. On the other hand, the content of MDA and SOD activity was increased as compared with control groups. Also, 2'CH3-MPTP showed severe histopathological changes including swelling of cytoplasm, interstitial edema, and complete loss of the neurons with reactive microglial proliferation and gliosis. Furthermore, histochemical examination of brain stem qualitatively showed depletion of dopaminergic neurons of nigrostriatum. Oral administration of TBHQ (100 mg/kg) prior to 2'CH3-MPTP for 7 days caused normalization of GSH content and SOD activity and ameliorated the MDA content but still above the control value. Pretreatment with TBHQ slightly mitigated the histopathological and histochemical changes observed in 2'CH3-MPTP-treated mice. Based on these observations, it can be concluded that the antioxidant TBHQ has the ability to reverse the oxidative stress caused by 2'CH3-MPTP in mice while failed to challenge the histopathological and histochemical changes induced by that toxicant. Copyright 2005 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15736157     DOI: 10.1002/jbt.20053

Source DB:  PubMed          Journal:  J Biochem Mol Toxicol        ISSN: 1095-6670            Impact factor:   3.642


  11 in total

1.  Developing neuroprotective strategies for treatment of HIV-associated neurocognitive dysfunction.

Authors:  Jeffrey A Rumbaugh; Joseph Steiner; Ned Sacktor; Avindra Nath
Journal:  Futur HIV Ther       Date:  2008

2.  Therapeutic potential and anti-amyloidosis mechanisms of tert-butylhydroquinone for Alzheimer's disease.

Authors:  Hasina Akhter; Ashwini Katre; Ling Li; Xuebo Liu; Rui-Ming Liu
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

3.  Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington's disease.

Authors:  Cliona Stack; Daniel Ho; Elizabeth Wille; Noel Y Calingasan; Charlotte Williams; Karen Liby; Michael Sporn; Magali Dumont; M Flint Beal
Journal:  Free Radic Biol Med       Date:  2010-03-23       Impact factor: 7.376

4.  Dietary supplementation with tBHQ, an Nrf2 stabilizer molecule, confers neuroprotection against apoptosis in amyloid β-injected rat.

Authors:  Fatemeh Nouhi; Solaleh Khoramian Tusi; Azadeh Abdi; Fariba Khodagholi
Journal:  Neurochem Res       Date:  2011-02-04       Impact factor: 3.996

5.  Enhancement of L-3-hydroxybutyryl-CoA dehydrogenase activity and circulating ketone body levels by pantethine. Relevance to dopaminergic injury.

Authors:  Emilie Cornille; Mhamad Abou-Hamdan; Michel Khrestchatisky; André Nieoullon; Max de Reggi; Bouchra Gharib
Journal:  BMC Neurosci       Date:  2010-04-23       Impact factor: 3.288

6.  Behavioral, Biochemical and Molecular Characterization of a Parkinson's Disease Mouse Model Using the Neurotoxin 2'-CH3-MPTP: A Novel Approach.

Authors:  Alice Laschuk Herlinger; Agihane Rodrigues Almeida; Sarah Martins Presti-Silva; Evaldo Vitor Pereira; Filipe Andrich; Rita Gomes Wanderley Pires; Cristina Martins-Silva
Journal:  Neuromolecular Med       Date:  2018-01-13       Impact factor: 3.843

Review 7.  Nrf2 as a potential target for Parkinson's disease therapy.

Authors:  Yingcai Niu; Jing Zhang; Miaoxian Dong
Journal:  J Mol Med (Berl)       Date:  2021-04-12       Impact factor: 4.599

8.  Nrf2/ARE Signaling Pathway: Key Mediator in Oxidative Stress and Potential Therapeutic Target in ALS.

Authors:  Susanne Petri; Sonja Körner; Mahmoud Kiaei
Journal:  Neurol Res Int       Date:  2012-09-20

9.  Lack of association between nuclear factor erythroid-derived 2-like 2 promoter gene polymorphisms and oxidative stress biomarkers in amyotrophic lateral sclerosis patients.

Authors:  Annalisa LoGerfo; Lucia Chico; Loredana Borgia; Lucia Petrozzi; Anna Rocchi; Antonia D'Amelio; Cecilia Carlesi; Elena Caldarazzo Ienco; Michelangelo Mancuso; Gabriele Siciliano
Journal:  Oxid Med Cell Longev       Date:  2014-02-09       Impact factor: 6.543

10.  Can tert-butylhydroquinone improve the healing of extracted tooth socket in rats?

Authors:  Somayeh Khoramian Tusi; Tahereh Eslam Manesh; Mahmood Sheikh Fathollahi; Ali Bagherian
Journal:  Dent Res J (Isfahan)       Date:  2017 Jan-Feb
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.